腎臟科醫師研究:吃中藥可以大幅度降低慢性腎臟病演變成末期腎病(要洗腎)的風險 - 台灣健保資料庫
![]()
腎病以及腎病皮膚問題,中醫經方的治療實例,請見部落格「腎病」分類(舊部落格)。
中醫經方治療前後,血檢數據的比對,請見部落格「血檢數據變化」分類。
期刊研究整理,請見期刊研究。
本篇研究全文,請見 PubMed(外部網站)。
原始論文
Lin MY, Chiu YW, Chang JS, Lin HL, et al. Kidney International. 2015;88(6):1365-1373. doi:10.1038/ki.2015.226
論文摘要(英文原文)
Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease
The evidence on whether Chinese herbal medicines affect outcome in patients with chronic kidney disease (CKD) is limited. Here we retrospectively explored the association of prescribed Chinese herbal medicine use and the risk of end-stage renal disease (ESRD) in patients with CKD. Patients with newly diagnosed CKD in the Taiwan National Health Insurance Research Database from 2000 to 2005 were categorized into new use or nonuse of prescribed Chinese herbal medicine groups. These patients were followed until death, dialysis initiation, or till the end of 2008. Among the 24,971 study patients, 11,351 were new users of prescribed Chinese herbal medicine after CKD diagnosis. Overall, after adjustment for confounding variables, the use group exhibited a significant 60% reduced ESRD risk (cause-specific hazard ratio 0.41, 95% confidence interval 0.37-0.46) compared with the nonuse group. The change was significantly large among patients using wind dampness-dispelling formulas (0.63, 0.51-0.77) or harmonizing formulas (0.59, 0.46-0.74), suggesting an independent association between specific Chinese herbal medicines and reduced ESRD risk. The findings were confirmed using propensity score matching, stratified analyses, and three weighting methods. However, dampness-dispelling and purgative formulas were associated with increased ESRD risk. Thus, specific Chinese herbal medicines are associated with reduced or enhanced ESRD risk in patients with CKD.
論文摘要(Google 翻譯)
以下為 Google 翻譯,並校正明顯錯誤,僅供參考,內容以英文原文為準。
慢性腎臟病患者中藥處方使用與末期腎病風險的關係
關於中草藥是否影響慢性腎臟病(CKD)患者預後的證據有限。在此,我們回顧性探討了 CKD 患者中藥處方使用與末期腎病(ESRD) 風險的關係。台灣全民健康保險研究資料庫中2000年至2005年新診斷CKD的患者被分為新使用或不使用處方中草藥組。對這些患者進行追蹤直至死亡、開始透析或直至 2008 年底。在 24,971 名研究患者中,11,351 名是 CKD 診斷後新服用中草藥的患者。總體而言,在調整干擾因子後,與未使用組別相比,使用組別的 ESRD 風險顯著降低了 60%(特定原因風險比 0.41,95% 信賴區間 0.37-0.46)。在使用祛風濕方(0.63,0.51-0.77)或調和方(0.59,0.46-0.74)的患者中,此變化顯著較大,顯示特定中草藥與降低 ESRD 風險之間存在獨立關聯。研究結果透過傾向分數配對、分層分析和三種加權方法得到證實。然而,祛濕方與瀉下方則與 ESRD 風險增加有關。因此,特定的中草藥與 CKD 患者 ESRD 風險的降低或升高有關。
原文發表於 作者部落格(舊部落格)。